Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21032600 | 0.88 | PDE2A (0.44) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL24910200 | 0.84 | ABCB11 (0.39) | PDE2ACES2NOTUMHSP90AA1HSP90AB1 | |
| SCHEMBL22717043 | 0.84 | PDE2A (0.61) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL19750893 | 0.84 | PDE2A (0.47) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL14121100 | 0.84 | PDE2A (0.43) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL23675536 | 0.84 | PDE2A (0.61) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL14121399 | 0.84 | PDE2A (0.43) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL22717245 | 0.84 | P2RX7 (0.47) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL2882405 | 0.84 | PDE2A (0.43) | PDE2ACES2HTR2AHTR2CHTR2B | |
| SCHEMBL19696153 | 0.84 | PDE2A (0.61) | PDE2ACES2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| WO-2023083269-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023070076-A1 | COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230026428-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4122934-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-20220407026-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-11466026-B2 | Organic electroluminescent materials and devices | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-11376241-B2 | Aryl hydrocarbon receptor (AhR) modulator compounds | PHENEX PHARMACEUTICALS AG (DE) | 2022-07-05 | — | — | US | disclosed |
| US-20220140252-A1 | NOVEL ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| WO-2008116156-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS ASSOCIATED WITH MITOCHONDRIAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PDE2A 2430/4885CES2 58/4885HTR2A 2793/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | PDE2A 1618/4885CES2 125/4885HTR2A 1305/4885 |
| US-11466026-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, SLCO4C1 | PDE2A 4676/4885CES2 890/4885HTR2A 2551/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PDE2A 2430/4885CES2 58/4885HTR2A 2793/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | PDE2A 3440/4885CES2 2956/4885HTR2A 4264/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PDE2A 2430/4885CES2 58/4885HTR2A 2793/4885 |
| US-20220407026-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | L1CAM, EPCAM, EML4 | PDE2A 4829/4885CES2 2294/4885HTR2A 2531/4885 |
| US-20220140252-A1 | NOVEL ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LEF1, PIEZO1, L1CAM | PDE2A 2795/4885CES2 2283/4885HTR2A 3611/4885 |
| US-20230026428-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, SLCO4C1 | PDE2A 4676/4885CES2 890/4885HTR2A 2551/4885 |
| US-11376241-B2 | Aryl hydrocarbon receptor (AhR) modulator compounds | AHR, ARNT, NR1H2 | PDE2A 3467/4885CES2 2258/4885HTR2A 215/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | PDE2A 2935/4885CES2 4162/4885HTR2A 3849/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | PDE2A 3798/4885CES2 3429/4885HTR2A 3855/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | PDE2A 2935/4885CES2 4162/4885HTR2A 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.